Current Status of Human Immunodeficiency Virus Vaccines
DOI:
https://doi.org/10.17140/VROJ-1-e002Abstract
Highly Active Antiretroviral Therapies (HAARTs) have been developed to treat HIV+ individuals, increasing the quality and quantity of life of many HIV+ patients. Despite these effective strategies, human immunodeficiency virus infection and acquired immune deficiency syndrome (HIV/AIDS) epidemic continues to uphold globally with 39 million infected individuals. 1 However, the HIV retrovirus integrates into the (cluster of differentiation 4) CD4+ cells’ genomes where it can persist for years in a latent stage forming HIV reservoirs throughout the body.2 Due to these reservoirs, infected individuals need to be under treatment for the rest of their lives, as HAARTs cannot fully cure HIV.3,4 As a result, preventive strategies have now been introduced in the plan to completely eradicate the HIV/AIDs endemic.5 Effective preventative strategies that decrease bodily fluids transmissions like the usage of condoms, sterile needles, abstinence, monogamy between uninfected individuals, and voluntary testing have been developed. The development of vaccines as preventative and treatment strategies against HIV has been proposed to aid in the eradication of this disease.5,6 Typically, vaccines have been successful in the disappearance of past endemics such as polio and small pox. Vaccine development for HIV began in the 1980’s.1 Two types of vaccines have been proposed: those as protection against acquisition of HIV-1 and those as treatment to cure HIV in conjunction with HAART.1,5
References
Sheets RL, Zhou T, Knezevic I. Review of efficacy trials of HIV-1/AIDS vaccines and regulatory lessons learned: A review from a regulatory perspective. Biologicals. 2016; 44(2): 73-89. doi: 10.1016/j.biologicals.2015.10.004
Nair M, Jayant RD, Kaushik A, Sagar V. Getting into the brain: Potential of nanotechnology in the management of NeuroAIDS. Adv Drug Deliv Rev. 2016; 103: 202-217. doi: 10.1016/j.addr.2016.02.008
Jayant RD, Atluri VS, Agudelo M, Sagar V, Kaushik A, Nair M. Sustained-release nanoART formulation for the treatment of neuroAIDS. Int J Nanomedicine. 2015; 10: 1077-1093. doi: 10.2147/IJN.S76517
Kaushik A, Jayant RD, Nair M. Advancements in Nano-enabled therapeutics for neuroHIV management. Int J Nanomedicine. 2016; 11: 1-9.
Autran B. Toward a cure for HIV-Seeking effective therapeutic vaccine strategies. Eur J Immunol. 2015; 45(12): 3215-3221. doi: 10.1002/eji.201545513
Vaccines. AIDS 2016. 2016. Web site. https://www.aids.gov/hiv-aids-basics/prevention/prevention-research/vaccines/. Accessed July 13, 2016
Excler J-L, Robb ML, Kim JH. Prospects for a globally effective HIV-1 vaccine. Vaccine. 2015; 33: D4-D12. doi: 10.1016/j.vac-cine.2015.03.059
Moodie Z, Janes H, Huang Y. New clinical trial designs for HIV vaccine evaluation. Curr Opin HIV AIDS. 2013; 8(5): 437-442. doi: 10.1097/COH.0b013e328363d46a
Day TA, Kublin JG. Lessons learned from HIV vaccine clinical efficacy trials. Curr HIV Res. 2013; 11(6): 441-449. doi:
2174/1570162X113116660051 10. NAM AIDS map. The RV144 trial. 2009. Web site. http://www.aidsmap.com/The-RV144-trial/page/2028003/. Accessed July 13, 2016
Gray GE, Laher F, Lazarus E, Ensoli B, Corey L. Approaches to preventative and therapeutic HIV vaccines. Curr Opin Virol. 2016; 17: 104-109. doi: 10.1016/j.coviro.2016.02.010
Chun T-W, Moir S, Fauci AS. HIV reservoirs as obstacles and opportunities for an HIV cure. Nat Immunol. 2015; 16(6): 584- 589. doi: 10.1038/ni.3152
Connolly NC, Whiteside TL, Wilson C, Kondragunta V, Rinaldo CR, Riddler SA. Therapeutic immunization with human immu-nodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals. Clin Vaccine Immunol. 2008; 15(2): 284-292. doi: 10.1128/CVI.00221-07
Macatangay BJ, Riddler SA, Wheeler ND, et al. Therapeutic vaccination with dendritic cells loaded with autologous HIV type 1-infected apoptotic cells. J Infect Dis. 2016; 213(9): 1400-1409. doi: 10.1093/infdis/jiv582
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Vaccination Research (VR) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.